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a b s t r a c t
Granulocytic sarcoma (GS) can occur de novo or in association with intramedullary myeloid disorders.
With the advent of sophisticated molecular detection techniques to detect diagnostic genes such as bcr-eceived in revised form 13 January 2009
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abl, PML-RARA and CBFB/MYH11 in bone marrow or peripheral blood, many cases of the so called ‘primary’
GS are questionable. We report a case of primary GS where the tumor mass bcr-abl translocation was
demonstrated by fluorescent in situ hybridization in which there was no evidence of chronic myeloid
leukemia (CML). This is an important finding as it highlights the possibility that CML may present as a




A myeloid sarcoma (MS) is a tumor mass consisting of myeloid
lasts with or without maturation occurring at an anatomical site
ther than the bone marrow [1]. Infiltrations of any site of the
ody by myeloid blasts in leukaemic patients are not classified
s MS unless they present with tumor masses in which the tis-
ue architecture is effaced [1]. This condition was first described
y Burns in 1811 [2]. King used ‘chloroma’ as the first term to
escribe this condition in 1853 [3]. The World Health Organiza-
ion (WHO) has renamed the condition as MS and divided it into
wo major categories, granulocytic sarcoma (GS) and monoblas-
ic sarcoma [4]. GS can arise de novo or can present concurrently
ith, after, or upon relapse with the diagnosis of myeloid dis-
rders. The best-known concurrent myeloid disorder is acute
yeloid leukemia (AML) [5]. Most untreated primary GS will
rogress into AML within 11 months [6,7]. Although the disease is
ssociated with chronic myeloid leukemia (CML) [5], myeloprolif-
rative disorders (MPD) [7,8] and myelodysplastic syndrome (MDS)
9,10], these conditions were never truly preceded by primary GS.
cr-abl fusion product is classically due to chromosomal translo-
ation t(9;22)(q34;q11) in CML. With the advent of fluorescent
n situ hybridization (FISH), bcr-abl translocation can be demon-
trated in the tumor cells of GS. As far as we know, this is the
rst reported case of FISH bcr-abl positive GS without CML and
ML.
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1.1. Case report
A 21-year-old Malay student presented to an otorhinolaryn-
gologist with bilateral bleeding nasal polyps in August 2006.
Diagnosis of GS was made from the bilateral excisional biopsy.
The biopsy showed immature lymphoid-type cells strongly pos-
itive for CD45 and negative for CD3, CD20, MNF116, S100, NSE,
HMB-45, ALK-1, and CD30. The cells exhibit focal positivity for
CD43, lysozyme and myeloperoxidase (MPO). The imaging evalua-
tion revealed sinonasal polypoidal masses extending into the right
maxillary, ethmoid, sphenoid and frontal sinuses. Bilateral nodal
masses in jugulodigastric chain and posterior triangles of the neck
were also seen. His full blood count (FBC), peripheral blood film
(PBF) and bone marrow (BM) examination were normal. BM cyto-
genetic examination showed a normal karyotype. He underwent
AML-like chemotherapy. He completed two courses of idarubin and
cytarabine induction chemotherapy, and one course of high dose
cytarabine as consolidation. Unfortunately, he was lost to follow up
after that.
Seven months later in late July 2007 he represented with recur-
rent and more extensive nasal tumor involving the paranasal
sinuses, left orbital cavity and anterior cranial fossa. The same
histopathological and immunological findings as in the initial
nasal biopsy were seen with strong CD43 positivity. FBC, PBF
and BM examination were normal. BM immunophenotyping did
not detect blast in the CD34/117 gate. BM cytogenetic was a
short spread, but FISH bcr-abl (LSI bcr-abl dual colour, dual fusion
probe Vysis, Abbott) was negative. He was given induction ther-
apy with idarubicin, cytarabine and intrathecal triple agents. While
waiting for local radiotherapy, he was given etoposide and cytara-
bine in September 2008, when at the same time a new scalp
swelling at right vertex region was noted. Although computed
